These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22152181)

  • 1. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
    Gold DT; Horne R; Coon CD; Price MA; Borenstein J; Varon SF; Satram-Hoang S; Macarios D
    Value Health; 2011 Dec; 14(8):1109-16. PubMed ID: 22152181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
    Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
    Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
    Kendler DL; Bessette L; Hill CD; Gold DT; Horne R; Varon SF; Borenstein J; Wang H; Man HS; Wagman RB; Siddhanti S; Macarios D; Bone HG
    Osteoporos Int; 2010 May; 21(5):837-46. PubMed ID: 19657689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women.
    Flood EM; Beusterien KM; Green H; Shikiar R; Baran RW; Amonkar MM; Cella D
    Health Qual Life Outcomes; 2006 Jul; 4():42. PubMed ID: 16834773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the osteoporosis patient satisfaction questionnaire (OPSQ).
    Lai PS; Chua SS; Chan SP; Low WY; Wong IC
    Maturitas; 2010 Jan; 65(1):55-63. PubMed ID: 19962839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.
    Kendler DL; Macarios D; Lillestol MJ; Moffett A; Satram-Hoang S; Huang J; Kaur P; Tang ET; Wagman RB; Horne R
    Menopause; 2014 Jan; 21(1):25-32. PubMed ID: 23676636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.
    Reynolds K; Viswanathan HN; O'Malley CD; Muntner P; Harrison TN; Cheetham TC; Hsu JW; Gold DT; Silverman S; Grauer A; Morisky DE
    Ann Pharmacother; 2012 May; 46(5):659-70. PubMed ID: 22510666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
    Oh KW; Kim DY; Lee YS; Kang MI;
    J Bone Miner Metab; 2012 May; 30(3):359-66. PubMed ID: 22083905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection.
    Tatlock S; Arbuckle R; Sanchez R; Grant L; Khan I; Manvelian G; Spertus JA
    Value Health; 2017 Mar; 20(3):430-440. PubMed ID: 28292488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
    Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
    Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trust in Nurses Scale: construct validity and internal reliability evaluation.
    Radwin LE; Cabral HJ
    J Adv Nurs; 2010 Mar; 66(3):683-9. PubMed ID: 20423403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a psychometric scale to assess satisfaction with dental care among Sri Lankans.
    Perera IR; Usgodaarachchi US
    Community Dent Health; 2009 Sep; 26(3):150-6. PubMed ID: 19780355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of mandatory generic substitution on the safety of alendronate and patients' adherence.
    Lai PS; Chua SS; Chong YH; Chan SP
    Curr Med Res Opin; 2012 Aug; 28(8):1347-55. PubMed ID: 22746354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.